30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Nongenomic effects via the mineralocorticoid receptor

2017/03/27 by Stefanie Ruhs, Alexander Nolze, Ralf Hübschmann +2 · 98 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Aldosterone #Angiotensin II #Biology #Blood pressure #Cardiovascular, Neuropeptides, and Oxidative Stress Research #Cell biology #Endocrinology #Hormonal Regulation and Hypertension #Internal medicine #Ion Transport and Channel Regulation #Medicine #Mineralocorticoid #Mineralocorticoid receptor #Receptor #Signal transduction

paper · pdf · doi:10.1530/joe-16-0659

published in Journal of Endocrinology 234(1), T107-T124 (Bioscientifica)

openalex publication_date 2017/03/27 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/25

Abstract

The mineralocorticoid receptor (MR) belongs to the steroid hormone receptor family and classically functions as a ligand-dependent transcription factor. It is involved in water-electrolyte homeostasis and blood pressure regulation but independent from these effects also furthers inflammation, fibrosis, hypertrophy and remodeling in cardiovascular tissues. Next to genomic effects, aldosterone elicits very rapid actions within minutes that do not require transcription or translation and that occur not only in classical MR epithelial target organs like kidney and colon but also in nonepithelial tissues like heart, vasculature and adipose tissue. Most of these effects can be mediated by classical MR and its crosstalk with different signaling cascades. Near the plasma membrane, the MR seems to be associated with caveolin and striatin as well as with receptor tyrosine kinases like EGFR, PDGFR and IGF1R and G protein-coupled receptors like AT1 and GPER1, which then mediate nongenomic aldosterone effects. GPER1 has also been named a putative novel MR. There is a close interaction and functional synergism between the genomic and the nongenomic signaling so that nongenomic signaling can lead to long-term effects and support genomic actions. Therefore, understanding nongenomic aldosterone/MR effects is of potential relevance for modulating genomic aldosterone effects and may provide additional targets for intervention.

Cited by

• Mineralocorticoid receptor inhibition in parietal epithelial cells prevents focal segmental glomerulosclerosis and crescentic glomerulonephritis
• Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
• Hormone [wikipedia]
• Glucocorticoid Receptor-mediated transactivation is hampered by Striatin-3, a novel interaction partner of the receptor. [europepmc]
• Communication between genomic and non-genomic signaling events coordinate steroid hormone actions. [europepmc]
• Roles of the Glucocorticoid and Mineralocorticoid Receptors in Skin Pathophysiology. [europepmc]
• Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease. [europepmc]
• Sex-specific deficits in biochemical but not behavioral responses to delay fear conditioning in prenatal alcohol exposure mice. [europepmc]
• The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications. [europepmc]
• Rapid Aldosterone-Mediated Signaling in the DCT Increases Activity of the Thiazide-Sensitive NaCl Cotransporter. [europepmc]
• The Correlation of Central Serous Chorioretinopathy and Subsequent Cardiovascular Diseases of Different Types: A Population-Based Cohort Study. [europepmc]
• Proteoglycans in the Pathogenesis of Hormone-Dependent Cancers: Mediators and Effectors. [europepmc]
• Central amygdala mineralocorticoid receptors modulate alcohol self-administration. [europepmc]
• Aging, hormones and receptors. [europepmc]
• The Interface of Nuclear and Membrane Steroid Signaling. [europepmc]
• OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs. [europepmc]
• Aldosterone Negatively Regulates Nrf2 Activity: An Additional Mechanism Contributing to Oxidative Stress and Vascular Dysfunction by Aldosterone. [europepmc]
• Concurrent Primary Aldosteronism and Renal Artery Stenosis: An Overlooked Condition Inducing Resistant Hypertension. [europepmc]
• Mineralocorticoid Receptor Signaling in the Inflammatory Skeletal Muscle Microenvironments of Muscular Dystrophy and Acute Injury. [europepmc]
• Aldosterone Increases Vascular Permeability in Rat Skin. [europepmc]
• Genetic Factors for Coronary Heart Disease and Their Mechanisms: A Meta-Analysis and Comprehensive Review of Common Variants from Genome-Wide Association Studies. [europepmc]
• Importance of Micromilieu for Pathophysiologic Mineralocorticoid Receptor Activity-When the Mineralocorticoid Receptor Resides in the Wrong Neighborhood. [europepmc]
• Cardiovascular Disease in Obstructive Sleep Apnea: Putative Contributions of Mineralocorticoid Receptors. [europepmc]
• The Effect of Aldosterone on Cardiorenal and Metabolic Systems. [europepmc]
• Aldosterone: Renal Action and Physiological Effects. [europepmc]
• Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). [europepmc]
• Autonomic Dysreflexia in Spinal Cord Injury: Mechanisms and Prospective Therapeutic Targets. [europepmc]
• Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest. [europepmc]

Related

• 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature
• Brain mineralocorticoid receptor in health and disease: From molecular signalling to cognitive and emotional function
• The Mineralocorticoid Receptor in the Vasculature: Friend or Foe?
• 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
• Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine